BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Women's health
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, November 19, 2024
See today's BioWorld Asia
See today's BioWorld MedTech
See today's BioWorld
Home
» Australia’s Cyclopharm raises AU$30M ahead of U.S. launch of Technegas for pulmonary embolism
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full article
sign up for free
or
sign in
.
Australia’s Cyclopharm raises AU$30M ahead of U.S. launch of Technegas for pulmonary embolism
Jan. 26, 2021
By
Tamra Sami
No Comments
PERTH, Australia – Sydney-based Cyclopharm Ltd. raised AU$30 million (US$23.19 million) in a private placement that will enable the company to launch its Technegas combination product in the U.S.
BioWorld
BioWorld MedTech
BioWorld Asia
Financings
Coronavirus
Private
Asia-Pacific
Australia